FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2086572083> ?p ?o ?g. }

• W2086572083 endingPage "2070" @default.
• W2086572083 startingPage "2061" @default.
• W2086572083 abstract "Bapineuzumab, a humanized anti-amyloid-beta (Abeta) monoclonal antibody for the potential treatment of Alzheimer disease (AD), was evaluated in a multiple ascending dose, safety, and efficacy study in mild to moderate AD.The study enrolled 234 patients, randomly assigned to IV bapineuzumab or placebo in 4 dose cohorts (0.15, 0.5, 1.0, or 2.0 mg/kg). Patients received 6 infusions, 13 weeks apart, with final assessments at week 78. The prespecified primary efficacy analysis in the modified intent-to-treat population assumed linear decline and compared treatment differences within dose cohorts on the Alzheimer's Disease Assessment Scale-Cognitive and Disability Assessment for Dementia. Exploratory analyses combined dose cohorts and did not assume a specific pattern of decline.No significant differences were found in the primary efficacy analysis. Exploratory analyses showed potential treatment differences (p < 0.05, unadjusted for multiple comparisons) on cognitive and functional endpoints in study completers and APOE epsilon4 noncarriers. Reversible vasogenic edema, detected on brain MRI in 12/124 (9.7%) bapineuzumab-treated patients, was more frequent in higher dose groups and APOE epsilon4 carriers. Six vasogenic edema patients were asymptomatic; 6 experienced transient symptoms.Primary efficacy outcomes in this phase 2 trial were not significant. Potential treatment differences in the exploratory analyses support further investigation of bapineuzumab in phase 3 with special attention to APOE epsilon4 carrier status.Due to varying doses and a lack of statistical precision, this Class II ascending dose trial provides insufficient evidence to support or refute a benefit of bapineuzumab." @default.
• W2086572083 created "2016-06-24" @default.
• W2086572083 creator A5001795846 @default.
• W2086572083 creator A5002183686 @default.
• W2086572083 creator A5002193113 @default.
• W2086572083 creator A5003680013 @default.
• W2086572083 creator A5014646926 @default.
• W2086572083 creator A5018836358 @default.
• W2086572083 creator A5025513316 @default.
• W2086572083 creator A5026400639 @default.
• W2086572083 creator A5026885325 @default.
• W2086572083 creator A5048338049 @default.
• W2086572083 creator A5059216826 @default.
• W2086572083 creator A5064783498 @default.
• W2086572083 creator A5068308578 @default.
• W2086572083 creator A5068394264 @default.
• W2086572083 creator A5076264560 @default.
• W2086572083 creator A5080281958 @default.
• W2086572083 creator A5081621207 @default.
• W2086572083 creator A5088718520 @default.
• W2086572083 date "2009-11-18" @default.
• W2086572083 modified "2023-10-14" @default.
• W2086572083 title "A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease" @default.
• W2086572083 cites W1567490604 @default.
• W2086572083 cites W1847168837 @default.
• W2086572083 cites W1953027527 @default.
• W2086572083 cites W1978873309 @default.
• W2086572083 cites W1987373495 @default.
• W2086572083 cites W1991952617 @default.
• W2086572083 cites W1991989649 @default.
• W2086572083 cites W1991993391 @default.
• W2086572083 cites W1996821202 @default.
• W2086572083 cites W2000917982 @default.
• W2086572083 cites W2006409771 @default.
• W2086572083 cites W2007350172 @default.
• W2086572083 cites W2017419067 @default.
• W2086572083 cites W2027278399 @default.
• W2086572083 cites W2045663319 @default.
• W2086572083 cites W2048139314 @default.
• W2086572083 cites W2069315029 @default.
• W2086572083 cites W2085851888 @default.
• W2086572083 cites W2088084445 @default.
• W2086572083 cites W2093508373 @default.
• W2086572083 cites W2096898082 @default.
• W2086572083 cites W2101128742 @default.
• W2086572083 cites W2109031511 @default.
• W2086572083 cites W2109727228 @default.
• W2086572083 cites W2109891655 @default.
• W2086572083 cites W2114613490 @default.
• W2086572083 cites W2119062449 @default.
• W2086572083 cites W2119128395 @default.
• W2086572083 cites W2121448546 @default.
• W2086572083 cites W2124135429 @default.
• W2086572083 cites W2146653387 @default.
• W2086572083 cites W2148034536 @default.
• W2086572083 cites W2148855559 @default.
• W2086572083 cites W2149086197 @default.
• W2086572083 cites W2152634927 @default.
• W2086572083 cites W2156220037 @default.
• W2086572083 cites W2157064933 @default.
• W2086572083 cites W2168891350 @default.
• W2086572083 cites W2231692891 @default.
• W2086572083 doi "https://doi.org/10.1212/wnl.0b013e3181c67808" @default.
• W2086572083 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/2790221" @default.
• W2086572083 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/20548049" @default.
• W2086572083 hasPublicationYear "2009" @default.
• W2086572083 type Work @default.
• W2086572083 sameAs 2086572083 @default.
• W2086572083 citedByCount "659" @default.
• W2086572083 countsByYear W20865720832012 @default.
• W2086572083 countsByYear W20865720832013 @default.
• W2086572083 countsByYear W20865720832014 @default.
• W2086572083 countsByYear W20865720832015 @default.
• W2086572083 countsByYear W20865720832016 @default.
• W2086572083 countsByYear W20865720832017 @default.
• W2086572083 countsByYear W20865720832018 @default.
• W2086572083 countsByYear W20865720832019 @default.
• W2086572083 countsByYear W20865720832020 @default.
• W2086572083 countsByYear W20865720832021 @default.
• W2086572083 countsByYear W20865720832022 @default.
• W2086572083 countsByYear W20865720832023 @default.
• W2086572083 crossrefType "journal-article" @default.
• W2086572083 hasAuthorship W2086572083A5001795846 @default.
• W2086572083 hasAuthorship W2086572083A5002183686 @default.
• W2086572083 hasAuthorship W2086572083A5002193113 @default.
• W2086572083 hasAuthorship W2086572083A5003680013 @default.
• W2086572083 hasAuthorship W2086572083A5014646926 @default.
• W2086572083 hasAuthorship W2086572083A5018836358 @default.
• W2086572083 hasAuthorship W2086572083A5025513316 @default.
• W2086572083 hasAuthorship W2086572083A5026400639 @default.
• W2086572083 hasAuthorship W2086572083A5026885325 @default.
• W2086572083 hasAuthorship W2086572083A5048338049 @default.
• W2086572083 hasAuthorship W2086572083A5059216826 @default.
• W2086572083 hasAuthorship W2086572083A5064783498 @default.
• W2086572083 hasAuthorship W2086572083A5068308578 @default.
• W2086572083 hasAuthorship W2086572083A5068394264 @default.
• W2086572083 hasAuthorship W2086572083A5076264560 @default.
• W2086572083 hasAuthorship W2086572083A5080281958 @default.

• next